These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35979371)

  • 21. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Adib E; Nassar AH; Akl EW; Abou Alaiwi S; Nuzzo PV; Mouhieddine TH; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Shukla SA; Gusev A; Braun DA; Choueiri TK; Kwiatkowski DJ
    Clin Cancer Res; 2021 Jul; 27(14):4025-4035. PubMed ID: 34074656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.
    Park JJ; Kellezi O; Hamasha R; Ali A; Alva AS
    Cancer Treat Res Commun; 2020; 25():100251. PubMed ID: 33310369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
    Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
    Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
    Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
    BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
    McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
    J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
    Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
    Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
    Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
    Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
    Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma.
    Dogan S; Xu B; Rana S; Chen H; Ghossein RA; Berger MF; Ho AL; Katabi N
    Mod Pathol; 2023 Jul; 36(7):100150. PubMed ID: 36841437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.
    Zhang C; Feng S; Tu Z; Sun J; Rui T; Zhang X; Huang H; Ling Q; Zheng S
    Cancer Med; 2021 Sep; 10(18):6227-6238. PubMed ID: 34331411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.
    Debien V; Thouvenin J; Lindner V; Barthélémy P; Lang H; Flippot R; Malouf GG
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
    Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.